Baseline demographic and descriptive characteristics
| Characteristic | Total (n = 84) | Placebo (n = 39) | Etanercept (n = 45) |
|---|---|---|---|
| *p<0.05 versus placebo, by analysis of variance (ANOVA); **p<0.01 versus placebo, by ANOVA; †one patient in each group took more than one DMARD. | |||
| DMARD, disease modifying antirheumatic drug; NSAID, non-steroidal anti-inflammatory drug. | |||
| Age (years), mean (SD) | 43.2 (10.6) | 40.7 (11.4) | 45.3 (9.5)* |
| Sex (men/women), % | 79/21 | 77/23 | 80/20 |
| Race (white/other), % | 94/6 | 95/5 | 93/7 |
| Disease duration (years), mean (SD) | 12.5 (8.9) | 9.7 (8.2) | 15.0 (8.8)** |
| Concomitant use of DMARD,† No (%) | 32 (38) | 16 (41) | 16 (36) |
| Hydroxychloroquine | 1 (1) | 1 (3) | 0 |
| Methotrexate | 11 (13) | 5 (13) | 6 (13) |
| Sulfasalazine | 22 (26) | 11 (28) | 11 (24) |
| Concomitant use of oral NSAID, No (%) | 73 (87) | 33 (85) | 40 (89) |
| Concomitant use of corticosteroid, No (%) | 13 (15) | 6 (15) | 7 (16) |
| Mean scores on ASAS components: | |||
| Spinal inflammation | 65.4 | 62.9 | 67.5 |
| Nocturnal and total back pain | 58.2 | 56.1 | 60.0 |
| Patient global assessment | 64.6 | 63.4 | 65.6 |
| Functional impairment | 58.8 | 57.2 | 60.2 |
| Mean BASDAI scores overall | 59.9 | 58.6 | 61.0 |
| BASDAI scores <40, No (%) | 10 (12) | 5 (13) | 4 (9) |